ADCT
NYSEADC Therapeutics SA
Price$1.04-0.07 (-5.86%)
12:00 PM01:30 PM
News · 26 weeks54+50%
2025-12-142026-06-07
Mix3190d
- SEC Filings13(42%)
- Insider8(26%)
- Earnings4(13%)
- Other4(13%)
- Analyst2(6%)
Latest news
25 items- ANALYSTADC Therapeutics downgraded by H.C. WainwrightH.C. Wainwright downgraded ADC Therapeutics from Buy to Neutral
- ANALYSTADC Therapeutics downgraded by RBC Capital Mkts with a new price targetRBC Capital Mkts downgraded ADC Therapeutics from Outperform to Sector Perform and set a new price target of $2.00
- INSIDERDirector Azelby Robert was granted 45,000 shares and covered exercise/tax liability with 12,600 shares, increasing direct ownership by 40% to 112,805 units (SEC Form 4) to cover withholding tax4 - ADC Therapeutics SA (0001771910) (Issuer)
- INSIDERDirector Squarer Ron was granted 45,000 shares and covered exercise/tax liability with 15,196 shares, increasing direct ownership by 32% to 123,431 units (SEC Form 4) to satisfy withholding obligation4 - ADC Therapeutics SA (0001771910) (Issuer)
- INSIDERDirector Sandor Victor was granted 45,000 shares and covered exercise/tax liability with 12,600 shares, increasing direct ownership by 30% to 140,686 units (SEC Form 4) (tax withholding)4 - ADC Therapeutics SA (0001771910) (Issuer)
- INSIDERDirector Monges Viviane was granted 45,000 shares and covered exercise/tax liability with 2,596 shares, increasing direct ownership by 29% to 186,447 units (SEC Form 4) to cover withholding tax4 - ADC Therapeutics SA (0001771910) (Issuer)
- INSIDERDirector Hug Peter was granted 45,000 shares and covered exercise/tax liability with 2,156 shares, increasing direct ownership by 19% to 263,344 units (SEC Form 4) to cover withholding tax4 - ADC Therapeutics SA (0001771910) (Issuer)
- INSIDERDirector Bizzari Jean-Pierre was granted 45,000 shares and covered exercise/tax liability with 12,600 shares, increasing direct ownership by 30% to 139,302 units (SEC Form 4) to satisfy withholding tax4 - ADC Therapeutics SA (0001771910) (Issuer)
- INSIDERDirector Coughlin Timothy was granted 45,000 shares and covered exercise/tax liability with 12,600 shares, increasing direct ownership by 81% to 72,400 units (SEC Form 4) (tax withholding)4 - ADC Therapeutics SA (0001771910) (Issuer)
- SECADC Therapeutics SA filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - ADC Therapeutics SA (0001771910) (Filer)
- PRADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in Relapsed or Refractory Diffuse Large B-Cell LymphomaCompany to host conference call today at 4:30 p.m. EDTLAUSANNE, Switzerland, June 3, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT) today announced topline data from its Phase 3 LOTIS-5 confirmatory trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). ZYNLONTA plus rituximab achieved statistical significance on the trial's primary endpoint of progression-free survival (PFS) and demonstrated no detrimental effect on the key secondary efficacy endpoint of overall survival (OS). In addition, a higher complete response (CR) rate and duration of CRs (DoCR) were observed with
- SECADC Therapeutics SA filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - ADC Therapeutics SA (0001771910) (Filer)
- SECSEC Form 10-Q filed by ADC Therapeutics SA10-Q - ADC Therapeutics SA (0001771910) (Filer)
- SECADC Therapeutics SA filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ADC Therapeutics SA (0001771910) (Filer)
- PRADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational UpdatesLOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year endFirst quarter 2026 net product revenue of $20.0 millionCash and cash equivalents of $231.0 million as of March 31, 2026, with an expected cash runway at least into 2028Company to host conference call today at 8:30 a.m. EDTLAUSANNE, Switzerland, May 4, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results for the first quarter ended March 31, 2026, and provided recent operational updates.
- PRADC Therapeutics Makes Grants to New Employees Under Inducement PlanLAUSANNE, Switzerland, May 1, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 49,400 of the Company's common shares to two new employees on May 1, 2026 (each, a "Grant"). The Grants were offered as material inducement to the employees' employment. The grants were approved by the Compensation Committee of the Company's Board of Directors pursuant to the Company's Inducement Plan to motivate and
- PRADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026LAUSANNE, Switzerland, April 27, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Monday, May 4, 2026, at 8:30 a.m. EDT to report financial results for the first quarter of 2026 and provide operational updates. To access the conference call, please register here. The participant toll-free dial-in number is 1-800-836-8184 for North America and Canada. It is recommended that you join 10 minutes before the event,
- SECAmendment: SEC Form SCHEDULE 13G/A filed by ADC Therapeutics SASCHEDULE 13G/A - ADC Therapeutics SA (0001771910) (Subject)
- SECSEC Form DEFA14A filed by ADC Therapeutics SADEFA14A - ADC Therapeutics SA (0001771910) (Filer)
- SECSEC Form DEF 14A filed by ADC Therapeutics SADEF 14A - ADC Therapeutics SA (0001771910) (Filer)
- SECSEC Form 424B3 filed by ADC Therapeutics SA424B3 - ADC Therapeutics SA (0001771910) (Filer)
- SECSEC Form PRE 14A filed by ADC Therapeutics SAPRE 14A - ADC Therapeutics SA (0001771910) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by ADC Therapeutics SASCHEDULE 13G/A - ADC Therapeutics SA (0001771910) (Subject)
- INSIDERSEC Form 4 filed by Redmile Group, Llc4 - ADC Therapeutics SA (0001771910) (Issuer)
- PRADC Therapeutics Announces New Employee Inducement GrantLAUSANNE, Switzerland, April 1, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made a grant of options to purchase an aggregate of 17,000 of the Company's common shares to a new employee on April 1, 2026 ("Grant"). The Grant was offered as material inducement to the employee's employment. The Grant was approved by the Compensation Committee of the Company's Board of Directors pursuant to the Company's Inducement Plan to motivate and reward the
ADCT FAQ
7 questionsWhat does ADC Therapeutics SA do?
ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its lead product candidates are loncastuximab tesirine (ADCT-402), an ADC that is in a Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, and Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL, as well as Phase I/II clinical trial in combination with ibrutinib for relapsed or...Where does ADCT stock trade?
ADC Therapeutics SA (ADCT) is listed on NYSE.What sector and industry is ADCT in?
ADC Therapeutics SA operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did ADC Therapeutics SA go public?
ADC Therapeutics SA (ADCT) completed its IPO in 2020.What are analysts saying about ADCT?
ADC Therapeutics SA has had 8 recent analyst actions on file. The most recent action was from H.C. Wainwright: Neutral on 2026-06-08.What companies are similar to ADCT?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ADCT side-by-side with any of them on Quantisnow.How can I track ADCT on Quantisnow?
Quantisnow aggregates ADC Therapeutics SA's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ADCT to receive live email and push alerts on every new disclosure.